Roka Bioscience, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens in the United States. It provides Atlas instrument, a fully automated molecular diagnostic testing instrument to reduce labor costs and operator error in high-volume foodborne pathogen testing laboratories. The company also offers atlas detection assays that include tests for Salmonella, Listeria, E. coli O157:H7, Shiga toxin-producing E. coli, and Listeria monocytogenes, as well as related consumable supplies. It serves contract testing labs, food processors, and government agencies. The company was founded in 2009 ...
20 Independence Boulevard
Warren, NJ 07059
Founded in 2009
Roka Bioscience, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:30 PM
Nov 25 14
Roka Bioscience, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Paul G. Thomas, Founder, Chief Executive Officer, President and Director.
Roka Bioscience, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
Roka Bioscience, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $1,483,000 against $556,000 a year ago. Loss from operations was $8,373,000 against $7,268,000 a year ago. Loss before income taxes was $9,072,000 against $9,414,000 a year ago. Net loss and comprehensive loss was $9,083,000 against $9,449,000 a year ago. Basic and diluted net loss per share was $0.64 against $17.00 a year ago. The increase in third quarter revenue year-on-year resulted from an increase in the number of Atlas(R) instruments placed with commercial customers and increased commercial utilization of the instruments.
For the nine months, the company reported revenue of $3,701,000 against $1,493,000 a year ago. Loss from operations was $22,742,000 against $22,194,000 a year ago. Loss before income taxes was $24,771,000 against $25,069,000 a year ago. Net loss and comprehensive loss was $24,799,000 against $25,105,000 a year ago. Basic and diluted net loss per share was $4.78 against $51.05 a year ago.
Roka Bioscience, Inc. to Report Q3, 2014 Results on Nov 06, 2014
Oct 30 14
Roka Bioscience, Inc. announced that they will report Q3, 2014 results After-Market on Nov 06, 2014